Stock-Based Compensation for Incyte (INCY)
Stock-Based Compensation for Incyte (INCY): headline value $190.33M · YoY -6.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
INCY
Currently viewingStock-Based CompensationSwitch metric
Latest period
$190.33M
YoY change
-6.3%
5Y CAGR
+7.0%
Peak year (2024)
$266.06M
Latest annual
$249.35M
Stock-Based Compensation history chart for Incyte (INCY) from 1993 to 2025
Stock-Based Compensation history table for Incyte (INCY) from 1993 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $249.35M | -6.3% | ||
| 2024 | $266.06M | +23.2% | ||
| 2023 | $215.89M | +14.6% | ||
| 2022 | $188.42M | +3.0% | ||
| 2021 | $183.01M | +2.9% | ||
| 2020 | $177.88M | +6.8% | ||
| 2019 | $166.59M | +12.4% | ||
| 2018 | $148.15M | +11.3% | ||
| 2017 | $133.06M | +38.3% | ||
| 2016 | $96.20M | +37.7% | ||
| 2015 | $69.87M | +12.4% | ||
| 2014 | $62.16M | +61.9% | ||
| 2013 | $38.40M | -0.2% | ||
| 2012 | $38.49M | +32.8% | ||
| 2011 | $28.98M | +95.1% | ||
| 2010 | $14.86M | +48.9% | ||
| 2009 | $9.98M | -33.6% | ||
| 2008 | $15.03M | +69.0% | ||
| 2007 | $8.89M | 0.0% | ||
| 2006 | $8.89M | +4679.6% | ||
| 2005 | $186,000 | -59.8% | ||
| 2004 | $463,000 | -88.7% | ||
| 2003 | $4.10M | 0.0% | ||
| 2002 | $4.10M | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — |
Stock-Based Compensation values are taken from Incyte's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Incyte (INCY) most recent annual stock-based compensation stands at $249.35M (2025) – declined 6.3% year-over-year.
Through 2020–2025 (5 years), Incyte stock-based compensation delivered a +7.0% annualised rate; with the latest reading among the more recent periods of the dataset.
The dataset's maximum stock-based compensation sits at $266.06M (2024); the minimum reading of $0 dates to 1993.
Within Healthcare, Incyte (INCY) ranks 5th among 8 peers we track. The peer median for stock-based compensation is $313.00M.
Incyte Stock-Based Compensation by Year
Incyte Stock-Based Compensation 2025: $249.35M
Incyte stock-based compensation in 2025 was $249.35M, declined 6.3% below 2024.
Incyte Stock-Based Compensation 2024: $266.06M
Incyte stock-based compensation in 2024 was $266.06M, grew 23.2% from 2023. This figure represents the highest annual value in the available history.
Incyte Stock-Based Compensation 2023: $215.89M
Incyte stock-based compensation in 2023 was $215.89M, grew 14.6% from 2022.
Incyte Stock-Based Compensation 2022: $188.42M
Incyte stock-based compensation in 2022 was $188.42M, edged up 3.0% from 2021.
Incyte Stock-Based Compensation 2021: $183.01M
Incyte stock-based compensation in 2021 was $183.01M.
See more financial history for Incyte (INCY).
Sector peers — Stock-Based Compensation
Companies in the same sector as Incyte, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Incyte's stock-based compensation?
Latest reported stock-based compensation for Incyte (INCY) is $190.33M (period ending March 31, 2026).
How has Incyte stock-based compensation changed year-over-year?
Incyte (INCY) stock-based compensation changed -6.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Incyte stock-based compensation?
Incyte (INCY) stock-based compensation compound annual growth rate is +7.0% over the most recent 5 years available.
When did Incyte stock-based compensation hit its highest annual value?
Incyte stock-based compensation reached its highest annual value of $266.06M in 2024.
What was Incyte stock-based compensation in 2024?
Incyte (INCY) stock-based compensation in 2024 was $266.06M.
What was Incyte stock-based compensation in 2025?
Incyte (INCY) stock-based compensation in 2025 was $249.35M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
INCY Overview
Company profile, financial tools, and key metrics
INCY Revenue Counter
Earns $170.00 every second. See per minute, hour, and day.
INCY Earnings Counter
Earns $45.40 per second net profit. See per minute, hour, and day.
INCY Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
INCY What If Invested
What if you had invested $1,000? See historical returns from any date.
INCY How It Makes Money
Discover visual breakdown of $5.36B in revenue — where it comes from and where it goes.
INCY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INCY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INCY Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
INCY Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
INCY Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.